Evidence map›Paper›PMID 35804333›Full record

ArticleBMC public health2022

Optimizing the World Health Organization algorithm for HIV vertical transmission risk assessment by adding maternal self-reported antiretroviral therapy adherence.

Sheila Fernández-Luis, Maria Grazia Lain, Miquel Serna-Pascual, Sara Domínguez-Rodríguez, Louise Kuhn, Afaaf Liberty, Shaun Barnabas, Elisa Lopez-Varela, Kennedy Otwombe, Siva Danaviah and 21 more

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 20 institutions in 8 countries.

Sheila Fernández-Luis *Centro de Investigação em Saúde de Manhiça (CISM), Bairro Cambeve, Rua 12, Distrito da Manhiça, CP 1929, Maputo, Mozambique. sheila.fernandez@isglobal.org.
Maria Grazia Lain *Fundação Ariel Glaser Contra o SIDA Pediátrico, Maputo, Mozambique. mlain@arielglaser.org.mz.
Miquel Serna-PascualPediatrics Department, Pediatric Research and Clinical Trials Unit (UPIC), Fundación para la Investigación Biomédica del Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (IMAS12), Madrid, Spain.
Sara Domínguez-RodríguezPediatrics Department, Pediatric Research and Clinical Trials Unit (UPIC), Fundación para la Investigación Biomédica del Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (IMAS12), Madrid, Spain.
Louise KuhnGertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Afaaf LibertyPerinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Shaun BarnabasFamily Center for Research with Ubuntu, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Elisa Lopez-VarelaCentro de Investigação em Saúde de Manhiça (CISM), Bairro Cambeve, Rua 12, Distrito da Manhiça, CP 1929, Maputo, Mozambique.
Kennedy OtwombePerinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Siva DanaviahAfrica Health Research Institute (AHRI), Durban, KwaZulu-Natal, South Africa.
Eleni NastouliGreat Ormond Street Institute for Child Health (GOS ICH), University College London (UCL), London, UK.
Paolo PalmaResearch Unit in Clinical Immunology and Vaccinology, Bambino Gesu' Children's Hospital, 00165, Rome, Italy.
Nicola CotugnoResearch Unit in Clinical Immunology and Vaccinology, Bambino Gesu' Children's Hospital, 00165, Rome, Italy.
Moira SpyerGreat Ormond Street Institute for Child Health (GOS ICH), University College London (UCL), London, UK.
Viviana GiannuzziFondazione per la Ricerca Farmacologica Gianni Benzi onlus, Valenzano, Italy.
Carlo GiaquintoDepartment of Mother and Child Health, University of Padova, Padova, Italy.
Avy ViolariPerinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Mark F CottonFamily Center for Research with Ubuntu, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Tacilta NhampossaCentro de Investigação em Saúde de Manhiça (CISM), Bairro Cambeve, Rua 12, Distrito da Manhiça, CP 1929, Maputo, Mozambique.
Nigel KleinAfrica Health Research Institute (AHRI), Durban, KwaZulu-Natal, South Africa.
Nastassja RamsagarPerinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Anita Janse van RensburgFamily Center for Research with Ubuntu, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Osee BehuhumaAfrica Health Research Institute (AHRI), Durban, KwaZulu-Natal, South Africa.
Paula VazFundação Ariel Glaser Contra o SIDA Pediátrico, Maputo, Mozambique.
Almoustapha Issiaka MaigaDepartment of Medical Biology, Gabriel Toure University Hospita, Bamako, Mali.
Andrea OlettoFondazione Penta ONLUS, Padova, Italy.
Denise NanicheCentro de Investigação em Saúde de Manhiça (CISM), Bairro Cambeve, Rua 12, Distrito da Manhiça, CP 1929, Maputo, Mozambique.
Paolo RossiAcademic Department of Pediatrics, Children's Hospital Bambino Gesù, Rome, Italy.
Pablo Rojo *Pediatrics Department, Pediatric Research and Clinical Trials Unit (UPIC), Fundación para la Investigación Biomédica del Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (IMAS12), Madrid, Spain.
Alfredo Tagarro *Pediatrics Department, Pediatric Research and Clinical Trials Unit (UPIC), Fundación para la Investigación Biomédica del Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (IMAS12), Madrid, Spain.
EPIICAL Consortium
Research Institute Hospital 12 de Octubre · ESUniversity of the Witwatersrand · ZAGreat Ormond Street Hospital · GBPENTA Foundation · ITUniversity of Rome Tor Vergata · ITFundação Ariel Glaser Contra o SIDA Pediátrico · MZManhiça Health Research Centre · MZUniversity of Padua · ITStellenbosch University · ZABambino Gesù Children's Hospital · ITBrigham and Women's Hospital · USChildren's Hospital Foundation · USJohns Hopkins University · USUniversity College London Hospitals NHS Foundation Trust · GBUniversity of Miami · USUtrecht University · NLAfrica Health Research Institute · ZACentre Hospitalier de l’Université de Montréal · CAColumbia University · USGianni Benzi Pharmacological Research Foundation · IT

Funding

University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ALLAN E RODRIGUEZ · 2007 to 2026
$33.8M
NIAID NIH HHS P30 AI073961
6 · The paper itself

Abstract

backgroundThe World Health Organization (WHO) risk assessment algorithm for vertical transmission of HIV (VT) assumes the availability of maternal viral load (VL) result at delivery and early viral control 4 weeks after initiating antiretroviral treatment (ART). However, in many low-and-middle-income countries, VL is often unavailable and mothers' ART adherence may be suboptimal. We evaluate the inclusion of the mothers' self-reported adherence into the established WHO-algorithm to identify infants eligible for enhanced post-natal prophylaxis when mothers' VL result is not available at delivery.

methodsWe used data from infants with perinatal HIV infection and their mothers enrolled from May-2018 to May-2020 in Mozambique, South Africa, and Mali. We retrospectively compared the performance of the WHO-algorithm with a modified algorithm which included mothers' adherence as an additional factor. Infants were considered at high risk if born from mothers without a VL result in the 4 weeks before delivery and with adherence <90%.

resultsAt delivery, 143/184(78%) women with HIV knew their status and were on ART. Only 17(12%) obtained a VL result within 4 weeks before delivery, and 13/17(76%) of them had VL ≥1000 copies/ml. From 126 women on ART without a recent VL result, 99(79%) had been on ART for over 4 weeks. 45/99(45%) women reported suboptimal (< 90%) adherence. A total of 81/184(44%) infants were classified as high risk of VT as per the WHO-algorithm. The modified algorithm including self-adherence disclosure identified 126/184(68%) high risk infants.

conclusionsIn the absence of a VL result, mothers' self-reported adherence at delivery increases the number of identified infants eligible to receive enhanced post-natal prophylaxis.

Indexed as

Anti-HIV AgentsHIV InfectionsPregnancy Complications, InfectiousAlgorithmsAnti-Retroviral AgentsFemaleHumansInfantInfectious Disease Transmission, VerticalMalePregnancyRetrospective StudiesRisk AssessmentSelf ReportWorld Health OrganizationAnti-HIV AgentsAnti-Retroviral AgentsEnhanced post-natal prophylaxisHIV-exposed infantsMother-to-child transmissionPaediatric HIVPrevention of mother-to-child transmissionVertical transmission

Identifiers

PMID35804333
PMCPMC9264598
OpenAlexW4284889772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.